Chipiron

Clinical trials now target cancer prevention for people without disease, covering medications, lifestyle, screening, and high-risk monitoring.
-...

A BI-RADS 4 or 5 result means a biopsy is needed—it is not a cancer diagnosis.

• BI-RADS 4 spans low-to-high suspicion; most findings prove benign...

Former FDA CDRH director Jeffrey Shuren's role at MedTech Innovator highlights why regulatory expertise is vital for medtech startups navigating FDA...

ASCO's updated guideline promotes a risk-based approach to follow-up frequency and intensity after primary breast cancer treatment, supporting virtual...

The Go Pink Expo shows how community events expand screening access by pairing free mammograms with mental-health resources, financial wellness info,...

UNC Health's $125 million commitment to its renamed venture arm signals health systems becoming strategic investors in medtech and health tech...

Women with BRCA1/2 pathogenic variants face markedly higher odds of choosing risk-reducing mastectomy and salpingo-oophorectomy over intensified...

AI-powered mammogram analysis now predicts five-year breast cancer risk more accurately than traditional models (AUC 0.72-0.73 vs 0.60-0.65) and is...

• Global scale-up: Radiology Partners acquires Everlight to unite vRad's US network with 800+ international radiologists for follow-the-sun coverage...

• GE HealthCare's Invenia ABUS Prime adds AI tools for 40% faster scans, standardized 3D ultrasound, and remote reading to support supplemental...

European guidelines now recommend extending organized mammography screening to all women aged 45-74, widening policy access for earlier breast cancer detection.

Three fronts show how AI is advancing breast imaging practice:

• Regulatory shift: FDA's competency-based framework evaluates generative AI devices...

MedTech startups often stall after university SBIR grants but before FDA approval—too early for VCs, too far for non-dilutive funds.

Fehmida...

The global breast MRI market is projected to expand from $2.50B in 2025 to $6.25B by 2035 at a 9.6% CAGR, signaling strong opportunities for investors...

Dorothy Larson faced a brutal reality after her 2001 breast cancer diagnosis: daily four-hour round trips to Greeley for seven weeks of radiation,...

Hyperfine's second FDA-cleared Optive AI update for the Swoop system sharpens image quality in noisy point-of-care spots like ICUs and EDs while...

Geographic isolation, racial disparities, and financial gaps continue blocking breast cancer screening despite local efforts.

• Geography: Michigan...

Calidar's Eidos Prism completed first-in-human testing with 61 patients, adding molecular imaging via volumetric X-ray diffraction to existing 3D mammography systems. The company is now preparing a multi-site pivotal study for 2027.

Medtech firms are accelerating carve-outs and spinouts as larger players shed non-core assets amid low valuations.

• Private equity is now actively...

AI-enhanced mammography is accelerating the transition from age-based to risk-based breast cancer screening by analyzing tissue patterns to predict...